Sana Biotechnology (NASDAQ:SANA) and Tectonic Therapeutic (NASDAQ:TECX) Head-To-Head Analysis

Tectonic Therapeutic (NASDAQ:TECX) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Institutional & Insider Ownership

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 9.2% of Tectonic Therapeutic shares are held by insiders. Comparatively, 31.1% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Tectonic Therapeutic and Sana Biotechnology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	$12.16 million	($5.89)	-6.60
Sana Biotechnology	N/A	N/A	-$283.26 million	($1.40)	-1.67

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tectonic Therapeutic has a beta of 2.6, suggesting that its stock price is 160% more volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Tectonic Therapeutic and Sana Biotechnology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	0	0	4	1	3.20
Sana Biotechnology	0	1	3	0	2.75

Tectonic Therapeutic currently has a consensus price target of $74.67, suggesting a potential upside of 92.04%. Sana Biotechnology has a consensus price target of $13.50, suggesting a potential upside of 476.92%. Given Sana Biotechnology’s higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Tectonic Therapeutic.

Profitability

This table compares Tectonic Therapeutic and Sana Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.53%	-31.97%
Sana Biotechnology	N/A	-84.22%	-44.97%

Summary

Tectonic Therapeutic beats Sana Biotechnology on 7 of the 12 factors compared between the two stocks.

About Tectonic Therapeutic

Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.

About Sana Biotechnology

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company’s product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin’s lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.